ALPINE GROUP PARTNERS, LLC. lobbying for ULTRAGENYX PHARMACEUTICAL INC.

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 3

ERIN MENDELSOHN

Previously held: LD, Rep. Anna Eshoo; Congressional Liaison - FDA
KEENAN AUSTIN REED

Previously held: Chief of Staff, Rep. Donald McEachin; Deputy Chief of Staff, Rep. Frederica S. Wilson
SHAYNE WOODS

Previously held: Senior Legislative Assistant, Sen. Tim Scott; Senior Policy Advisor, Rep. Gus Bilirakis

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)

Government Issues

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)

Medical/Disease Research/Clinical Labs

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)